SEARCH OUR PRODUCT CATALOG

One Cell Systems and Empire Genomics Initiate DNA Probe Product Development and Distribution Agreement

2013-02-21 21:31:44

CAMBRIDGE, MA and BUFFALO, NY, Nov 10, 2008 (MARKET WIRE via COMTEX) -- One Cell Systems, Inc. and Empire Genomics LLC today announced a broad DNA probe product development and distribution agreement in which Empire will develop locus specific DNA probes for One Cell for slide based fluorescent in situ hybridization (FISH) applications. In addition, Empire will be able to co-market One Cell's existing synthetic oligonucleotide probes for chromosome enumeration. The first product the two firms will launch in January 2009 will make it possible to enumerate all 24 human chromosomes within 24 hours, a critical requirement for the Preimplantation Genetic Diagnosis (PGD) segment of the IVF market.


"This Agreement allows One Cell to fill gaps in its product line for the oncology, PGD, and prenatal markets," said Ed O'Lear, COO, One Cell Systems, Inc. "The immediate ability to access Empire's proprietary BAC clones is complementary with our patent pending synthetic oligonucleotide probes. Our oligos allow for the primary diagnosis of solid tumors. With Empire's BAC library we can quickly develop probes to detect chromosomal deletions, inversions, and translocations that are critical for the cancer's progression. Also, Empire's relationship with the Roswell Park Cancer Institute will accelerate our collective product development."
"Working with One Cell and their expertise in probe development and protocol optimization affords Empire with a tremendous competitive advantage. We look forward to launching many new products in the market over the coming months," said Anthony Johnson, Empire's President and CEO.


About One Cell Systems
One Cell Systems, Inc. is a privately owned biotechnology company focused on developing, manufacturing, and marketing assays and reagents for clinical diagnostics, patient management, and general research applications. The Company licensed the synthetic oligonulcleotide technology from Cellay LLC and introduced its oligo FISH probes for chromosome enumeration in January 2008. One Cell's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, please visit www.onecell.com


About Empire Genomics
Empire Genomics, based in Buffalo, New York, utilizes proprietary techniques to identify and quantify chromosomal abnormalities. Specifically the company has evolved array-based Comparative Genomic Hybridization (aCGH) by developing microarrays that utilize discrete segments of DNA generated from the RPCI BAC clones. These are of considerable diagnostic value to early stage disease detection and treatment, and streamline the process by eliminating the need to grow cells or obtain large sample amounts. The company was founded on the research experience of Dr. Norma Nowak and her more than 100 peer reviewed research publications. More information on Empire Genomics is available at www.empiregenomics.com.


CONTACT:

Edward O'Lear
Chief Operating Officer
617-868-2399ext. 302
100 Inman Street
Cambridge, MA 02139
Tel 617-868-2399
Fax 617-492-1679


Anthony Johnson
President/CEO
701 Ellicott Street, Suite 203
Buffalo, NY 14203
Tel 800-715-5880
Fax 716-849-6890